Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + Myocet in metastatic breast cancer
2006-000120-14Phase 2Active
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- Mar 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and docetaxel in breast cancer, sponsored by Azienda USL Toscana Nord Ovest. Primary endpoint: Objective response rate. Started Mar 2006; status: active.
02
Drugs
doxorubicindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-000120-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000120-14.